Tegsedi Gets Innovative Medication Category Pricing in Brazil

Tegsedi Gets Innovative Medication Category Pricing in Brazil

309577

Tegsedi Gets Innovative Medication Category Pricing in Brazil

Tegsedi (inotersen), an approved treatment for familial amyloid polyneuropathy (FAP), has received a Category 1 classification by the legal body tasked with economic regulation of medications in Brazil. Category 1 is given by Câmara de Regulação do Mercado de Medicamentos to innovative treatments that are more effective than current standards of care, and allows for pricing in line with international markets, according to PTC Therapeutics, the company marketing Tegsedi in Latin America. “This is an…

You must be logged in to read/download the full post.